Company performance
Add to research
Current Price
as of Mar 21, 2025$1.20
P/E Ratio
N/A
Market Cap
$94.3M
Description
Add to research
SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.
Metrics
Add to research
Overview
- HQNew York, NY
- SectorHealth Technology
- IndustryPharmaceuticals: Major
- TickerSLS
- Price$1.2-0.83%
Trading Information
- Market cap$94.30M
- Float97.92%
- Average Daily Volume (1m)896,358
- Average Daily Volume (3m)2,614,464
- EPS-$0.50
Company
- RevenueN/A
- Rev growth (1yr)N/A
- Net income-$30.88M
- Gross marginN/A
- EBITDA marginN/A
- EBITDA-$31.51M
- EV$50.67M
- EV/RevenueN/A
- P/EN/A
- P/SN/A
- P/B9.38
- Debt/Equity10.58
Documents
Add to research
SEC Filings
Factset Street Account